Donor selection process for allogeneic hematopoietic stem cell transplantation at the University Hospital of Dusseldorf (1997-1998)

被引:5
|
作者
Enczmann, J
Rinker, M
Kiesel, U
Kuhröber, A
Kögler, G
Nürnberger, W
Göbel, U
Wernet, P
机构
[1] Univ Dusseldorf, Med Ctr, Bone Marrow Donor Ctr, D-4000 Dusseldorf, Germany
[2] Univ Dusseldorf, Med Ctr, Eurocord Bank & Transplantat Immunol, D-4000 Dusseldorf, Germany
[3] Univ Dusseldorf, Med Ctr, Dept Pediat Hematol & Oncol, D-4000 Dusseldorf, Germany
来源
KLINISCHE PADIATRIE | 1999年 / 211卷 / 04期
关键词
hematopoietic stem cell transplantation; donor election; unrelated allogeneic donor; selection criteria;
D O I
10.1055/s-2008-1043792
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Background: Transplantation of hematopoietic stem cells (HSC) is an effective treatment for a number of patients with life-threatening hematologic diseases. HSC donors can be: found in the family of the patient or in registries of unrelated donors. In the present study, the search procedure within the last two years for an allogeneic HSC donor at the University of Dusseldorf is analyzed. Patients and methods: During 1997 and 1998, an early search for a related HSC donor in the family was performed for 70 high risk pediatric patients. During the same period, the search for an unrelated HSC donor for 116 adult and pediatric patients was performed. Law resolution HLA-A and -B typing was performed by serology in combination with DNA-typing. High resolution typing of HLA-A, -B and -C was carried out by DNA-sequencing. Low resolution HLA-D RE - und HLA-D QB1-typing was done solely by DNA-typing and high resolution typing of these genes was performed by DNA-sequencing. Main Results: For 51 of 70 high risk pediatric patients (73%), no family donor could be defined, 16 of 70 patients (23%) had a genotypically identical sibling and for three of 70 patients (4%) an HLA-acceptable donor in the extended family could be identified. The search for an unrelated HSC donor was successful in 74% of the adult and pediatric patients lacking such a family donor. Most noteworthy, nearly all of the HLA-acceptable donors were identified from that group of donors in the registries, which were not only HLA-A and HLA-B, but also HLA-DR pretyped. Conclusion: These data show, that a growing number of pediatric patients with high risk leukemia need an unrelated HSC donor and that HLA-ABDR-pretyped registries present the optimal prerequisite to identify an HSC donor for most of the patients. In addition, 25% of the patients with no family or unrelated HSC donor require HSC transplants from alternative donors like unrelated Cord Blood (CB) from high quality cord blood banks.
引用
收藏
页码:218 / 223
页数:6
相关论文
共 50 条
  • [41] Unrelated donor choices for allogeneic hematopoietic cell transplantation in Canada: an evaluation of factors influencing donor selection
    Greco-Stewart, Valerie
    Kiernan, Jeffrey
    Killeen, Donna
    Haun, Sherry
    Mercer, Dena
    Young, Kimberly
    Liwski, Robert S.
    Allan, David S.
    TRANSFUSION, 2018, 58 (03) : 718 - 725
  • [42] Late Donor Bone Marrow Failure After Allogeneic Hematopoietic Stem Cell Transplantation
    Meunier, Mathieu
    Manez, Anne-Claire
    Xhaard, Alienor
    de Latour, Regis Peffault
    de Fontbrune, Flore Sicre
    Dhedin, Nathalie
    Socie, Gerard
    Robin, Marie
    TRANSPLANTATION, 2014, 97 (12) : E75 - E77
  • [43] Successful treatment of Griscelli syndrome with unrelated donor allogeneic hematopoietic stem cell transplantation
    M Aricò
    M Zecca
    N Santoro
    D Caselli
    R Maccario
    C Danesino
    G de Saint Basile
    F Locatelli
    Bone Marrow Transplantation, 2002, 29 : 995 - 998
  • [44] Lung epithelial cells of donor origin after allogeneic hematopoietic stem cell transplantation
    Mattsson, J
    Jansson, M
    Wernersson, A
    Barkholt, L
    Hassan, M
    BONE MARROW TRANSPLANTATION, 2003, 31 : S248 - S248
  • [45] Successful treatment of Griscelli syndrome with unrelated donor allogeneic hematopoietic stem cell transplantation
    Aricò, M
    Zecca, M
    Santoro, N
    Caselli, D
    Maccario, R
    Danesino, C
    Basile, GD
    Locatelli, F
    BONE MARROW TRANSPLANTATION, 2002, 29 (12) : 995 - 998
  • [46] Donor lymphocyte infusion for the treatment of relapse after allogeneic hematopoietic stem cell transplantation
    Helg, C
    Starobinski, M
    Jeannet, M
    Chapuis, B
    LEUKEMIA & LYMPHOMA, 1998, 29 (3-4) : 301 - 313
  • [47] EFFECT OF DONOR KIR GENOTYPE ON THE OUTCOME OF PEDIATRIC ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
    Koo, H. H.
    Lee, S. H.
    Lee, J. W.
    Yoo, K. H.
    Sung, K. W.
    Kang, E. S.
    Kim, S. J.
    Kim, K.
    Jang, J. H.
    Jung, C. W.
    HAEMATOLOGICA, 2016, 101 : 630 - 630
  • [48] Allogeneic related donor hematopoietic stem cell transplantation for treatment of chronic lymphocytic leukemia
    Doney, KC
    Chauncey, T
    Appelbaum, FR
    BONE MARROW TRANSPLANTATION, 2002, 29 (10) : 817 - 823
  • [49] Hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation: donor type matters
    El-Zimaity, M
    Saliba, R
    Chan, K
    Shahjahan, M
    Carrasco, A
    Khorshid, O
    Caldera, H
    Couriel, D
    Giralt, S
    Khouri, I
    Ippoliti, C
    Champlin, R
    de Lima, M
    BLOOD, 2004, 103 (12) : 4674 - 4680
  • [50] Donor-Derived Malignancy and Transplantation Morbidity: Risks of Patient and Donor Genetics in Allogeneic Hematopoietic Stem Cell Transplantation
    Williams, Lacey S.
    Williams, Kirsten M.
    Gillis, Nancy
    Bolton, Kelly
    Damm, Frederik
    Deuitch, Natalie T.
    Farhadfar, Nosha
    Gergis, Usama
    Keel, Sioban B.
    Michelis, Fotios, V
    Panch, Sandhya R.
    Porter, Christopher C.
    Sucheston-Campbell, Lara
    Tamari, Roni
    Stefanski, Heather E.
    Godley, Lucy A.
    Lai, Catherine
    TRANSPLANTATION AND CELLULAR THERAPY, 2024, 30 (03): : 255 - 267